377740 — Bionote Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedSmall CapNeutral

Annual income statement for Bionote, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	R2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	622,355	479,657	90,081	102,780	118,324
Cost of Revenue
Gross Profit	512,064	340,732	-11,569	51,240	65,768
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	153,608	331,511	145,531	76,503	101,627
Operating Profit	468,748	148,146	-55,450	26,277	16,696
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	869,885	414,778	-109,491	73,327	-87,568
Provision for Income Taxes
Net Income After Taxes	676,601	307,798	-20,497	55,261	-87,498
Net Income Before Extraordinary Items
Net Income	676,601	307,798	-20,497	55,261	-87,498
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	676,601	307,798	-20,497	55,261	-87,498
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	7,221	3,996	-149	438	-855
Dividends per Share